Esperion Therapeutics (ESPR) Free Cash Flow Growth (1y) (2013 - 2026)
Esperion Therapeutics (ESPR) Free Cash Flow Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 10.34% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -13.65% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 56.40% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -5.85% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -29.32% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 166.91% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 44.93% |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | -23.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.35% |
| Dec 31, 2025 | 228.90% |
| Sep 30, 2025 | 87.92% |
| Jun 30, 2025 | -330.50% |
| Mar 31, 2025 | -142.09% |
| Dec 31, 2024 | 5.68% |
| Sep 30, 2024 | -83.57% |
| Jun 30, 2024 | 70.51% |
| Mar 31, 2024 | 198.89% |
| Dec 31, 2023 | 12.75% |
| Sep 30, 2023 | 54.88% |
| Jun 30, 2023 | 51.02% |
| Mar 31, 2023 | -39.41% |
| Dec 31, 2022 | 26.40% |
| Sep 30, 2022 | 38.07% |
| Jun 30, 2022 | -5.57% |
| Mar 31, 2022 | 56.22% |
| Dec 31, 2021 | 16.03% |
| Sep 30, 2021 | 20.12% |
| Jun 30, 2021 | -134.48% |